Rocket
Premium
Excel Add-In
International
Tools
Dashboard
Screener
Spinoffs
IPOs
Register
Alerts
Sign In
Overview
Financials
News + Filings
Key Docs
Charts
Ownership
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
COMPUGEN LTD (CGEN)
Create:
Alert
All
|
News
|
Filings
Date Filed
Type
Description
08/23/2023
20-F/A
Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]
08/07/2023
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
Notice of 2023 annual general meeting of shareholders of Compugen Ltd., proxy statement and proxy card
",
"
Notice of 2023 annual general meeting of shareholders of Compugen Ltd., proxy statement and proxy card
"
08/07/2023
6-K
Quarterly results
Docs:
"
6-K
",
"
Compugen Reports Second Quarter 2023 Results
",
"
F-2 - F-3 Condensed Consolidated Statements of Comprehensive Loss F-4 Condensed Consolidated Statements of Changes in Shareholders' Equity F-5 Condensed Consolidated Statements of Cash Flows F-6 Notes to Condensed Consolidated Financial Statements F-7 - F-15
",
"
MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION
"
06/13/2023
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
6-K
",
"
Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement
"
05/15/2023
6-K
Quarterly results
Docs:
"
6-K
",
"
Compugen Reports First Quarter 2023 Results
"
05/03/2023
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
6-K
"
04/14/2023
F-3/A
Form F-3/A - Registration statement by foreign private issuers: [Amend]
03/10/2023
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
6-K
"
03/06/2023
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
Compugen Doses First Patient in Triple Combination COM701, COM902 and Pembrolizumab MSS CRC Proof of Concept Study
",
"
Compugen Doses First Patient in Triple Combination COM701, COM902 and Pembrolizumab MSS CRC Proof of Concept Study
"
02/28/2023
20-F
Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
02/27/2023
6-K
Quarterly results
Docs:
"
6-K
",
"
Compugen Reports Fourth Quarter and Full Year 2022 Results
"
02/14/2023
6-K
Quarterly results
02/10/2023
SC 13G/A
Nikko Asset Management Americas, Inc. reports a 0% stake in Compugen, Ltd.
02/03/2023
SC 13G/A
Sumitomo Mitsui Trust Holdings, Inc. reports a 0% stake in Compugen, Ltd.
01/31/2023
6-K
Quarterly results
01/31/2023
424B5
Form 424B5 - Prospectus [Rule 424(b)(5)]:
12/06/2022
6-K
Quarterly results
12/02/2022
6-K
Quarterly results
12/01/2022
6-K
Quarterly results
11/16/2022
6-K
Quarterly results
11/14/2022
6-K
Quarterly results
11/07/2022
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
6-K
",
"
Compugen’s COM701 (anti-PVRIG) in Combination with Nivolumab Demonstrates Preliminary Anti-Tumor Activity and Potent Immune Activation in Metastatic MSS-CRC Patients
",
"
Compugen’s COM701 (anti-PVRIG) Induces Potent Immune Activation in MSS-CRC Patients
"
11/02/2022
6-K
Quarterly results
09/22/2022
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
6-K
",
"
Compugen Letter to Shareholders
"
09/15/2022
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
6-K
"
09/12/2022
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
6-K
",
"
Compugen Announces Appointment of Alberto Sessa as Chief Financial Officer
"
08/04/2022
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans:
08/04/2022
6-K
Quarterly results
08/04/2022
6-K
Quarterly results
08/04/2022
6-K
Quarterly results
08/04/2022
6-K
Quarterly results
05/16/2022
6-K
Quarterly results
05/10/2022
6-K
Quarterly results
02/28/2022
20-F/A
Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]
Next >>
Rocket Data Systems, Inc. © 2019 |
Contact Us
|
Data Disclaimer
|
Terms of Use
|
Privacy